1. Home
  2. BGNE vs WBD Comparison

BGNE vs WBD Comparison

Compare BGNE & WBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BGNE
  • WBD
  • Stock Information
  • Founded
  • BGNE 2010
  • WBD 1923
  • Country
  • BGNE Cayman Islands
  • WBD United States
  • Employees
  • BGNE N/A
  • WBD N/A
  • Industry
  • BGNE Biotechnology: Pharmaceutical Preparations
  • WBD Cable & Other Pay Television Services
  • Sector
  • BGNE Health Care
  • WBD Telecommunications
  • Exchange
  • BGNE Nasdaq
  • WBD Nasdaq
  • Market Cap
  • BGNE 21.0B
  • WBD 18.1B
  • IPO Year
  • BGNE 2016
  • WBD N/A
  • Fundamental
  • Price
  • BGNE $189.23
  • WBD $9.22
  • Analyst Decision
  • BGNE Buy
  • WBD Buy
  • Analyst Count
  • BGNE 7
  • WBD 20
  • Target Price
  • BGNE $247.07
  • WBD $10.75
  • AVG Volume (30 Days)
  • BGNE 281.8K
  • WBD 32.8M
  • Earning Date
  • BGNE 11-12-2024
  • WBD 11-07-2024
  • Dividend Yield
  • BGNE N/A
  • WBD N/A
  • EPS Growth
  • BGNE N/A
  • WBD N/A
  • EPS
  • BGNE N/A
  • WBD N/A
  • Revenue
  • BGNE $3,351,304,621.00
  • WBD $39,578,000,000.00
  • Revenue This Year
  • BGNE $969.39
  • WBD N/A
  • Revenue Next Year
  • BGNE $24.79
  • WBD $1.25
  • P/E Ratio
  • BGNE N/A
  • WBD N/A
  • Revenue Growth
  • BGNE 50.22
  • WBD N/A
  • 52 Week Low
  • BGNE $126.97
  • WBD $6.64
  • 52 Week High
  • BGNE $248.16
  • WBD $12.70
  • Technical
  • Relative Strength Index (RSI)
  • BGNE 31.72
  • WBD 61.68
  • Support Level
  • BGNE $189.60
  • WBD $9.08
  • Resistance Level
  • BGNE $209.29
  • WBD $9.95
  • Average True Range (ATR)
  • BGNE 6.42
  • WBD 0.41
  • MACD
  • BGNE -2.10
  • WBD 0.15
  • Stochastic Oscillator
  • BGNE 9.19
  • WBD 70.33

About BGNE BeiGene Ltd.

BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.

About WBD Warner Bros. Discovery Inc. Series A

Warner Bros. Discovery was formed in 2022 through the combination of WarnerMedia and Discovery Communications. It operates in three global business segments: studios, networks, and direct-to-consumer. Warner Bros. Pictures is the crown jewel of the studios business, producing, distributing, and licensing movies and television shows. The networks business consists of basic cable networks, such as CNN, TNT, TBS, Discovery, HGTV, and the Food Network. Direct-to-consumer includes HBO and the firm's streaming platforms, which have now been consolidated to Max and Discovery+. Much of the DTC content is created within the firm's other two business segments. Each segment operates with a global reach, with Max available in over 60 countries.

Share on Social Networks: